Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2022 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer | Geyer, C E; Garber, J E; Gelber, R D; Yothers, G; Taboada, M; Ross, L; Rastogi, P; CHIUN-SHENG HUANG ; et al., | Annals of oncology : official journal of the European Society for Medical Oncology | 128 | 67 |